Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 30, 1999

View Archived Issues

Connetics expands dermatology pipeline

Gene mutation identified as cause of Papillon-Lefevre syndrome

Vitex receives milestone investment for progress with Inactine

Biopure expands phase III Hemopure clinical trial into Canada

GelTex and Sankyo finalize agreements for CholestaGel and second-generation product

Elan confirms arrangements for purchase of Axogen

AxyS Advanced Technologies and Cephalon to collaborate in combinatorial chemistry

Schwarz, ARYx team up to design novel antiarrhythmic drugs

Reboxetine + pindolol rapidly relieves symptoms of depression and other CNS disorders

FDA approves new treatment for respiratory failure in neonates

AstraZeneca seeks approval of Atacand HCT in the U.S.

Schwarz obtains expanded rights to develop and market antiparkinsonian patch

Potent, nonpeptide angiotensin II receptor antagonists discovered at Chinese university

Japanese approval obtained for Relenza

Byk Gulden compounds exhibit potent anti-H. pylori activity

Benzofurans with cardioprotective, anxiolytic activity designed at Egis

International patent covers AHP's new antidiabetic agents

Japanese labs discover new imidazoles useful for liver disease

Warner-Lambert reports R&D progress in the area of kinase inhibitors

Altropane detects abnormal increases in brain DATs in patients with longstanding ADHD

Crinone associated with reduced implantation, pregnancy rates following IVF-ET

Elan seeks U.S. approval for ziconotide

Boston Life Sciences to meet with FDA regarding Therafectin

Expanded patent protection for Theratechnologies' GRF analogue program

Irbesartan and other selective AT1 receptor antagonists may offer new approach to stroke management

FDA approves Ligand's Targretin Capsules for treatment of CTCL

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 22, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...